Other long-lasting formulations for the treatment of Parkinson’s disease include PLGA microparticles (delivery of VEGF [354] and GDNF) [354,355,356,357,358], PLGA-collagen microparticles (delivery of GDNF fused with collagen binding peptide) [359] and poly(butyl cyanoacrylate) nanoparticles (delivery of nerve growth factor, NGF) [360]. The gene discussed is GDNF; the disease is Parkinson disease.